Related references
Note: Only part of the references are listed.Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine
Hanna Seitz et al.
CANCER PREVENTION RESEARCH (2015)
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies
Joshua W. Wang et al.
CLINICAL AND VACCINE IMMUNOLOGY (2015)
Management of Cutaneous Warts of the Hand
Daniel J. Miller et al.
JOURNAL OF HAND SURGERY-AMERICAN VOLUME (2015)
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2015)
A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls
Timo Vesikari et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Human Papillomaviruses and Non-melanoma Skin Cancer
Margaret E. McLaughlin-Drubin
SEMINARS IN ONCOLOGY (2015)
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes
Subhashini Jagu et al.
VACCINE (2015)
Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2
Ebenezer Tumban et al.
VACCINE (2015)
Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach
Wai-Hong Wu et al.
VIROLOGY JOURNAL (2015)
Immunologic Control of Mus musculus Papillomavirus Type 1
Joshua W. Wang et al.
PLOS PATHOGENS (2015)
Immunoprevention of Human Papillomavirus-Associated Malignancies
Joshua W. Wang et al.
CANCER PREVENTION RESEARCH (2015)
Human Beta-papillomavirus infection and keratinocyte carcinomas
Koen D. Quint et al.
JOURNAL OF PATHOLOGY (2015)
Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+Cancer
Shiwen Peng et al.
PLOS ONE (2015)
Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions
Joshua W. Wang et al.
PLOS ONE (2014)
Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes
Kirin Kalnin et al.
VACCINE (2014)
Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing
Mitchell Tyler et al.
VACCINE (2014)
Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies
Joshua W. Wang et al.
VIROLOGY (2014)
Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
Tae Jin Kim et al.
NATURE COMMUNICATIONS (2014)
A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope
Elena Canali et al.
SCIENTIFIC REPORTS (2014)
Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+T cells
Shiwen Peng et al.
CELL AND BIOSCIENCE (2014)
Influence of Oxidation and Multimerization on the Immunogenicity of a Thioredoxin-L2 Prophylactic Papillomavirus Vaccine
Hanna Seitz et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses
Christina Schellenbacher et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Phylogenetic Considerations in Designing a Broadly Protective Multimeric L2 Vaccine
Subhashini Jagu et al.
JOURNAL OF VIROLOGY (2013)
Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras
Catherine B. Pineo et al.
PLANT BIOTECHNOLOGY JOURNAL (2013)
Optimization of Multimeric Human Papillomavirus L2 Vaccines
Subhashini Jagu et al.
PLOS ONE (2013)
A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvants
Ebenezer Tumban et al.
VACCINE (2013)
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Talia Malagon et al.
LANCET INFECTIOUS DISEASES (2012)
Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate
Karen Nieto et al.
PLOS ONE (2012)
VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus
Ebenezer Tumban et al.
PLOS ONE (2012)
Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice
Sun-Woo Yoon et al.
VACCINE (2012)
The Biology and Life-Cycle of Human Papillomaviruses
John Doorbar et al.
VACCINE (2012)
A randomized trial of immunotherapy for persistent genital warts
David Jardine et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2
Ebenezer Tumban et al.
PLOS ONE (2011)
The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies
Ivonne Rubio et al.
VIROLOGY (2011)
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
S. Daayana et al.
BRITISH JOURNAL OF CANCER (2010)
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Patricia M. Day et al.
CELL HOST & MICROBE (2010)
Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches
M. Saveria Campo et al.
JOURNAL OF VIROLOGY (2010)
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7
Jerri do Carmo Caldeira et al.
VACCINE (2010)
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Hans-Ulrich Bernard et al.
VIROLOGY (2010)
Expression Pattern and Subcellular Localization of Human Papillomavirus Minor Capsid Protein L2
Zhenhua Lin et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines
Subhashini Jagu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines
Christina Schellenbacher et al.
JOURNAL OF VIROLOGY (2009)
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity
Balasubramanyam Karanam et al.
VACCINE (2009)
Immunogenicity of an HPV-16 L2 DNA vaccine
Inga I. Hitzeroth et al.
VACCINE (2009)
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin
Ivonne Rubio et al.
VACCINE (2009)
Papillomaviruses in the causation of human cancers - a brief historical account
Harald zur Hausen
VIROLOGY (2009)
Skin cancer in organ transplant recipients -: Where do we stand today?
C. Ulrich et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes
Kazunari Kondo et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Arrangement of L2 within the papillomavirus capsid
Christopher B. Buck et al.
JOURNAL OF VIROLOGY (2008)
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2
Hannah H. Alphs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Generation and characterization of a preventive and therapeutic HPV DNA vaccine
Daejin Kim et al.
VACCINE (2008)
A protective and broadly cross-neutralizing epitope of human papillomavirus L2
Ratish Gambhira et al.
JOURNAL OF VIROLOGY (2007)
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Andrew E. Grulich et al.
LANCET (2007)
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
Jeffrey N. Roberts et al.
NATURE MEDICINE (2007)
Case-control study of human papillomavirus and oropharyngeal cancer
Gypsyamber D'Souza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species
Ratish Gambhira et al.
CANCER RESEARCH (2006)
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes
Kenneth E. Palmer et al.
VACCINE (2006)
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial
AN Fiander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine:: Infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination
P Vandepapelière et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine
D Nardelli-Haefliger et al.
VACCINE (2005)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
Against which human papillomavirus types shall we vaccinate and screen?: The international perspective
N Muñoz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)
EJ Davidson et al.
VACCINE (2004)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination
LJC Smyth et al.
CLINICAL CANCER RESEARCH (2004)
Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers
K Kawana et al.
VACCINE (2003)
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16
A Varsani et al.
JOURNAL OF VIROLOGY (2003)
Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Muñoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles
B Chackerian et al.
JOURNAL OF IMMUNOLOGY (2002)
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
A de Jong et al.
VACCINE (2002)
Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen
WF Cheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens
SH van der Burg et al.
VACCINE (2001)
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA
S Gerber et al.
JOURNAL OF VIROLOGY (2001)
Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies
K Kawana et al.
VACCINE (2001)
Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection
R Han et al.
VACCINE (2000)
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
RBS Roden et al.
VIROLOGY (2000)
Share Paper
